Treating hepatitis C can improve one factor of heart function.
In patients with chronic hepatitis C (HCV) who achieve sustained virologic response (SVR), combination treatment with pegylated interferon (pegIFN) and ribavirin (RBV) has no adverse effects on cardiac function, according to results published in The American Journal of the Medical Sciences.
In addition, the results indicated that viral eradication improved left ventricular diastolic dysfunction in patients with chronic HCV.
The study included treatment-naïve participants with HCV (n=142). Participants were treated with combination pegIFN/RBV. The researchers assessed and correlated cardiac function by determining cardiac biomarkers and echocardiography at baseline and for 24 weeks post-treatment.
Overall, 50.7% of participants achieved SVR. All participants had significantly higher serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at baseline. In participants who achieved SVR, these levels decreased significantly 24 weeks post-treatment (62.84 [36.98-102.73] vs 22.87 [15.64-56.92] pg/mL, respectively; P <.01).
All participants with SVR had significantly lower peak early diastolic annular velocity (E′) was significantly lower (7.69 ± 2.48 vs 9.74 ± 2.68 cm/s; P <.001), while E/E′ was higher (10.04 ± 2.51 vs 8.18 ± 2.31; P <.001).
There were no statistically significant differences in biomarkers and echocardiographic parameters in participants with and without SVR.
|Read on: Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C|